We like Pharmedic (HNX: PMC) for its strong brands, good products, healthy financial positions, and profitability. But post retirement age management and full capacity utilization with no clear expansion plan stand as limits to its growth story. In addition, poor liquidity of the stock on market is also a considerable risk. The stock is now trading at FY13F PER of 7.1x pegged to FY13F earnings.